306 related articles for article (PubMed ID: 17928466)
1. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients.
Cattaneo D; Cortinovis M; Baldelli S; Bitto A; Gotti E; Remuzzi G; Perico N
Clin J Am Soc Nephrol; 2007 Nov; 2(6):1147-55. PubMed ID: 17928466
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft.
Neumann I; Fuhrmann H; Kanzler M; Fang IF; Jaeger A; Graf H; Bayer P; Kovarik J
Expert Opin Pharmacother; 2008 Apr; 9(6):879-86. PubMed ID: 18377332
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis.
Czock D; Rasche FM; Carius A; Glander P; Budde K; Bauer S; Keller F; von Müller L
J Clin Pharmacol; 2007 Jul; 47(7):850-9. PubMed ID: 17526858
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.
Tedesco-Silva H; Bastien MC; Choi L; Felipe C; Campestrini J; Picard F; Schmouder R
Transplant Proc; 2005 Mar; 37(2):852-5. PubMed ID: 15848554
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers.
Rupprecht K; Schmidt C; Raspé A; Schweda F; Shipkova M; Fischer W; Bucher M; Kees F; Faerber L
J Clin Pharmacol; 2009 Oct; 49(10):1196-201. PubMed ID: 19783713
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients.
Johnston A; He X; Holt DW
Transplantation; 2006 Dec; 82(11):1413-8. PubMed ID: 17164710
[TBL] [Abstract][Full Text] [Related]
7. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
[TBL] [Abstract][Full Text] [Related]
8. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.
Capone D; Tarantino G; Kadilli I; Polichetti G; Basile V; Federico S; Sabbatini M
Nephrol Dial Transplant; 2011 Sep; 26(9):3019-25. PubMed ID: 21317409
[TBL] [Abstract][Full Text] [Related]
9. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A
Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135
[TBL] [Abstract][Full Text] [Related]
10. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients.
Sollinger H
Transplant Proc; 2004 Mar; 36(2 Suppl):517S-520S. PubMed ID: 15041399
[TBL] [Abstract][Full Text] [Related]
11. Conversion to enteric-coated mycophenolate sodium from mycophenolate mofetil in stable renal transplant patients: results of an Asia-Pacific study.
Lee PH; Vathsala A; Han DJ; Chan TM; Wong HS; Woodcock C; Kurstjens N;
Nephrology (Carlton); 2013 Jan; 18(1):57-62. PubMed ID: 23113863
[TBL] [Abstract][Full Text] [Related]
12. Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients.
Tedesco-Silva H; Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Slade A; Schmouder R; Medina-Pestana JO
Clin Transplant; 2010; 24(4):E116-23. PubMed ID: 20047618
[TBL] [Abstract][Full Text] [Related]
13. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients.
Böhler T; Canivet C; Galvani S; Therville N; Salvayre R; Negre-Salvayre A; Durand D; Thomsen M; Rostaing L; Kamar N
Int Immunopharmacol; 2008 May; 8(5):769-73. PubMed ID: 18387521
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients.
Hummel M; Yonan N; Ross H; Miller LW; Sechaud R; Balez S; Koelle EU; Gerosa G;
Clin Transplant; 2007; 21(1):18-23. PubMed ID: 17302587
[TBL] [Abstract][Full Text] [Related]
16. Absorption characteristics of EC-MPS--an enteric-coated formulation of mycophenolic sodium.
Arns W; Gies M; Choi L; Zhu W; Cooper P; Yeh CM; Prasad P; Graf P; Schmouder R
Int J Clin Pharmacol Ther; 2006 Aug; 44(8):375-85. PubMed ID: 16961168
[TBL] [Abstract][Full Text] [Related]
17. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.
Arns W; Breuer S; Choudhury S; Taccard G; Lee J; Binder V; Roettele J; Schmouder R
Clin Transplant; 2005 Apr; 19(2):199-206. PubMed ID: 15740555
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation.
Belliere J; Esposito L; Gandia P; Duffas JP; Sallusto F; Cardeau-Desangles I; Del Bello A; Rostaing L; Kamar N
Ann Transplant; 2014 Feb; 19():76-81. PubMed ID: 24509827
[TBL] [Abstract][Full Text] [Related]
19. Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data.
Trkulja V; Lalić Z; Nađ-Škegro S; Lebo A; Granić P; Lovrić M; Pasini J; Božina N
Ther Drug Monit; 2014 Aug; 36(4):456-64. PubMed ID: 24518562
[TBL] [Abstract][Full Text] [Related]
20. Changes in the small bowel of symptomatic kidney transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Bunnapradist S; Sampaio MS; Wilkinson AH; Pham PT; Huang E; Kuo HT; Anastasi B; Danovitch GM; Lo SK
Am J Nephrol; 2014; 40(2):184-90. PubMed ID: 25196230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
